中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

1783 records (took 0.04 seconds)

    Augmented reality display system and method
    67.
    发明授权
    Augmented reality display system and method 有权

    公开(公告)号：US11368670B2

    公开(公告)日：2022-06-21

    申请号：US16758471

    申请日：2018-10-25

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD.

    Inventor： Shimon Ullman ,  Daniel Harari ,  Liav Assif ,  Igal Koifman

    IPC: H04N13/388 ,  G02B27/01 ,  G06T19/00 ,  G06V20/20

    Abstract: A multi-layer viewing system includes a stationary imager and a beam projector to project physical layer markings onto a region of an object. A headset includes an augmented reality display that is sufficiently transparent to enable a user who is wearing the headset to directly view the object through the display, and to display annotation that is superimposed on the object. A processor is configured to receive a selected location relative to the target for display of the annotation, determine an orientation of the augmented reality display by identifying images of markings in acquired images or markings on the object, calculate a display location for displaying the annotation on the augmented reality display such that the annotation is perceivable by the user as displayed at the selected position, and display the annotation at the calculated display location.

    Biomarkers for CNS Disease Modification
    69.
    发明申请
    Biomarkers for CNS Disease Modification 有权

    公开(公告)号：US20220146534A1

    公开(公告)日：2022-05-12

    申请号：US17423769

    申请日：2020-01-16

    Applicant: Yeda Research and Development, Co., Ltd.

    Inventor： Michal Eisenbach-Schwartz ,  Hila Ben-Yehuda ,  Michal Arad ,  Tommaso Croese ,  Javier Maria Peralta Ramos ,  Giulia Castellani ,  Neta Rosenzweig

    IPC: G01N33/68 ,  G01N33/50

    Abstract: A method for predicting whether a patient diagnosed with a disease, disorder, condition or injury of the CNS is likely to be responsive or non-responsive to treatment with an immune checkpoint modulator is provided, wherein said method comprises determining ex vivo, in a blood sample obtained from the patient, or in a fraction thereof, a biomarker selected from: (a) the level of a monocyte subpopulation expressing CCR2, CD204 or a combination thereof, or CCR2 and a marker selected from igf1, lyve1, Stab-1, Siglec1 and Mrc1, or any combination thereof, (b) the ratio of the level of a monocyte subpopulation (CD14+ cells) expressing CCR2highCX3CR1low to a monocyte subpopulation expressing CCR2lowCX3CR1high; (c) the level of a CCR2 agonist; and (d) the level of a CCR2 antagonist.

    Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease
    70.
    发明授权
    Redirected, genetically-engineered T regulatory cells and their use in suppression of autoimmune and inflammatory disease 有权

    公开(公告)号：US11326147B2

    公开(公告)日：2022-05-10

    申请号：US16361852

    申请日：2019-03-22

    Applicant: YEDA RESEARCH AND DEVELOPMENT CO., LTD.

    Inventor： Zelig Eshhar ,  Eran Elinav

    IPC: C12N5/0783 ,  A61K39/00

    Abstract: A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.

Patent Agency Ranking